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Abstract
Protein–lipid binding interactions control many processes at the cellular level. Many of
these biological events between proteins and lipids are often associated with signaling pathway
diseases such as cancer and diabetes. Therefore, increasing our knowledge of protein–lipid
binding interactions will provide a better understanding of the signaling pathways of living
systems. Pursuing this further, the phosphatidylinositol polyphosphates (PIPs) are an important
family of signaling lipids that control key biological processes. Thus, the work described in this
thesis was aimed at developing methods to validate these types of lipid–protein binding
interactions. The goals of these projects were to synthesize the PIP compound and investigate
protein lipid interactions with this compound and others already synthesized using microarray
analysis via a pin printer. The results at this juncture in chapter 1 discuss how we were able to
achieve successful printing of our target compound as well as determine that binding was
occurring. Due to the nature of the microarray we were not able to determine Kd [surface
dissociation constant] values for protein–lipid binding interactions due to the fact of not having
enough positive data in a singular test event.
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Chapter 1:

Design, Synthesis, and Studies of
Phosphatidylinositol 3,4,5–trisphosphate Probe

1.1 Background and Significance of Phospholipids in Biological
Processes
Phospholipids are a specific class of lipids that are major components of cell membranes
and other lipid bilayers. Individual Phospholipids differ based on their headgroup, and
biologically relevant examples include phosphatidylcholine (PC), phosphatidylethanolamine
(PE), phosphatidylserine (PS), phosphatidic acid (PA), and phosphatidylinositol (PI). They are all
comprised of a triacylglycerol backbone with two of the alcohols containing fatty acid chains
and the third comprised of a functional headgroup.
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Figure 1.1 Physical Structure of Phospholipids

In general, all of the phospholipids play important roles of various aptitudes in biological
systems with our interest lying specifically with the phosphatidylinositol polyphosphate (PIPs)
and how they interact with different proteins. The PIPs are often site-specific in their
interactions, which enforce membrane-association of protein binding partners. There are a
total of seven naturally occurring PIPn isomers, each of which has some manner of regulation in
different pathways. The difference between each of the PIP isomers varies only in the
phosphorylation pattern of the core headgroup which consists of D-myo-inositol ring, with
every combination of the 3, 4 or 5 positions being phosphorylated and present in nature.
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These are all D-myo-inositols due to the IUPAC systematic naming of cyclitols. Absolute
configuration is determined by making a vertical Fischer-Tollens projection of the compound,
with C-1 at the top and with C-2 and C-3 on the front edge of the ring. Following this further,
the configuration is designated D if the lowest numbered carbon bearing a hydroxyl group
projects to the right, and as L if pointing to the left.
Many of the pathways of proteins that interact with PIPs are significantly mutationprone/aberrant in disease. For example, diabetes and cancer metathesis are both associated
with upregulation of PIP3. Thus, learning about the types and multitude of binding interactions
with the target lipids will help develop diagnostic methods for detecting processes that are
upregulated in disease. The mechanisms by which PIPs control disease-related processes are
complex in nature. PI3K1 and phosphatase tensin homolog (PTEN)2 are among the most heavily
mutated oncogenes and tumor suppressors in cancer. Hyper-activation of this signaling
pathway has been revealed to create cell stresses and apoptosis.3 Moreover, the deregulation
of this pathway stimulates tumor suppression.4
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Figure 1.2: The PI3K/Akt pathway: PI3K phosphorylates PIP2 to PIP3 which recruits
Akt and PDK to the cell membrane. PDK then activates Akt by phosphorylation, which
activates many downstream pathways that control cell growth. The reversible
reaction takes place with PTEN5 converting PIP3 back to PIP2. PI3K and PTEN are
commonly mutated in cancer.

Following this further, blocking the production of the inositol pyrophosphate IP7, a well
known small molecule involved in signaling pathways,6 facilitates the recruitment of Akt by PIP3,
and has a key role in glucose homeostasis, which serves to protect mice against obesity and
insulin resistance,7 thereby promoting cell growth and survival. After being recruited to the
membrane by PIP3, the activation of Akt by kinases such as protein dependant kinase (PDK)
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deters cell death processes by supporting cell growth. In addition, this activation of Akt helps
to promote protein synthesis pathways enabling Akt to continue downstream to promote
healthy cell life. We can see the many cellular signaling events such as cell proliferation,
transformation, cell shape, motility, insulin action, and the altering of glucose transport all
involve PIP3.8.
The first goal of the work described in this thesis was to synthesize an amine conjugated
phosphatidylinositol 3,4,5–trisphosphate (PIP3) probe scheme 1.1 (compound 19) that can be
exploited for microarray analysis. Our second goal was to investigate multivalent protein
binding studies with a phosphatidylinositol 4,5–bisphosphate (PIP2) probe and profilin. Human
profilin 1 protein is a known tumor suppressor that is involved in regulation of the
cytoskeleton.9 We sought to measure binding affinities of profilin for PIP2 as a function of ligand
density to understand the effect of multivalency detection from cancer cell extracts.
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1.2 Microarray Analysis of Binding between PIPs and Proteins
Microarray analysis of protein–lipid binding interactions is beneficial due to its highthroughput nature. Previous studies by our group showed the ability to detect protein–lipid
binding on microarray slides.10 Grid A was printed at a constant concentration of 500 µM PIP3
while grid B was printed at varying concentrations from 0 to 500 µM left to right of PIP 3. Both
grids were incubated with purified Akt PH domain at a constant concentration of 1.1 µM and
protein binding was detected using fluorescent antibodies. These results prove the high affinity
of PIP3 binding to Akt.

A

B

Figure 1.3: Microarray: Previous results from our
group from microarray analysis of PIP3–Akt binding10.
This established proof of concept for our microarray
system, which we extended via the current studies.
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Effectively designing PIP probes will enhance the opportunity to successfully study the
protein–lipid multivalent binding interactions of profilin and univalent binding of Akt and other
PIP binding proteins. We have developed biotinylated PIP headgroups such as 21 for microarray
analysis. Certain proteins, including Akt and Profilin, bind predominantly to the phosphorylated
inositol headgroup (S-type proteins), while others interact with the interfacial membrane
region (I-type proteins), and lastly a third binding mode involves substantial dissemination of
protein into the hydrophobic membrane core (H-type proteins). Previous studies have shown
PIP2 and PIP3 to be headgroup-driven binding lipids (S-type), with electrostatic attraction
primarily driving the interaction of the protein with the phosphorylated myo-inositol
headgroup.11,12,13 Thus, simplified PIP probes lacking the glycerolipid backbone are effective for
studies.

7

Scheme 1.1: Synthetic Scheme of PIP3 Analogs
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Scheme 1.1

Using a previously reported procedure14,4 the synthesis of PIP3 probe 21 began with
TBDPS-camphor protected triol 10, which was protected with benzoyl groups to access 11. The
camphor protecting group of 11 was then removed to provide 12. Next, a third benzoyl group
was introduced at the 3 position to yield 13. The diol 13 was protected at the 2 and 6 positions
with benzyloxymethyl groups generating 14. Next, the benzoyl groups of 14 were removed
producing the triol 15. The triol 15 was then phosphorylated at the 3, 4 and 5 positions to yield
compound 16. Continuing further, the trisphosphate 16 was deprotected at the 1 position
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providing 17. Next, the alcohol 17 was phosphorylated yielding the fully protected PIP3
probe 18. Compound 18 was globally deprotected to yield 19. The amine 19 can have a biotin
tag attached in one step to yield 21 for microarray studies which had previously been made by
Meng in our group, or 19 can be exploited via amide bond formation and then protected to
yield 20. The tail of 19 contains an amine that can be derivitized to an amide for labeling with
different photoaffinity tags for covalent labeling of proteins. The yields obtained thus far match
the reported literature fairly closely except step 16 to 17. It is hypothesized that this is due to
TBAF being hygroscopic in nature and moisture being absorbed over time.
Microarray technology is on the forefront of this investigation with its ability to
manipulate and control ligand presentation on surfaces, and since small amounts of lipid and
protein are used while allowing for maximal data output. The strategy was to incubate and bind
the PIP biotinylated headgroup or the amine headgroup onto streptavidin-coated glass slides or
epoxide-coated glass slides, followed by thorough buffer washes. Next, the ligand was
incubated with purified profilin followed by further buffer washes to remove unbound protein.
An anti-profilin rabbit-conjugated goat anti-rabbit Cy3 antibody was then used to label the
profilin, followed by further washing. Finally, fluorescence-based detection at 532 nm using a
slide scanner was performed to transduce the presence of bound protein.
It is important to run control experiments to establish binding involved with the protein
target. These controls are used to demonstrate that labeling of profilin involves specific binding
and that the Cy3 tagged antibody is crucial for detection of fluorescence. Studies with profilin
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have demonstrated that it fails to bind monovalently to headgroups at physiologically relevant
concentrations but has a high affinity for multivalent binding of phosphoinositide headgroups,
promoting the need to understand this interaction at the molecular level.15

Figure 1.4: Microarray-based assay for the
detection of receptor–PIP headgroup binding
interactions
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The goal of these studies is to determine the effect of density on protein–lipid binding in
these studies to understand how this regulates binding affinity. Thus, determination of binding
affinity with changing different ligand densities will need to be found for various concentrations
of proteins. The signal intensity in an array depends on the surface density16, so it will be
essential to normalize PIP concentrations prior to printing the microarray. Determination of the
dissociation constant will be performed by printing increasing concentration of PIP onto each
grid of the glass slide. The difference between each grid will be the amount of protein
incubated onto each grid. Therefore, by measuring the increase in incubated protein
concentration versus the fluorescence from the resulting protein binding, we will obtain
Langmuir isotherms for each ligand concentration, as Wong and associates have previously
shown with carbohydrate–protein binding.16
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Figure 1.5: Multivalent Density Studies: Example of increasing [PIP2] left to right within
each grid while increasing [Profilin] for separate grids. This allows for multiple Kd
affinity curves to be determined. Kd can then be plotted versus [PIP2] on the surface.
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In previous carbohydrate–protein multivalency studies, both a threshold type of
binding, in which the binding significantly increased after a certain density of ligand, and a
gradient type of binding, in which increasing the density of the ligand continually reduced the
dissociation constant, have been observed.16,17 This allowed determination of the amount of
ligand needed to produce maximal amount of fluorescent response. In our studies, we have
taken a similar approach to this prior work. We sought to print multiple grids with varying
concentration of ligand, and then fluorescence detection using a slide scanner was pursued to
determine relative intensity versus concentration, in order to calculate Kd.

Threshold Binding

Kd

Kd

Gradient Binding

Density of α-GalCer

Density of Man1

Figure 1.6: Examples of the effects of ligand clustering on dissociation constant
from prior carbohydrate studies.16,17

It should be noted that we hoped to see a point in the concentration of PIP2–profilin
binding where the value of Kd significantly increased at a low concentration of PIP2. Profilin
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binding should be significantly affected by multivalency since this protein is believed to
bind in a ~6:1 ratio of PIP to profilin, as determined by sedimentation equilibrium
experiments.15 If we have too little concentration of PIP2 on the glass slide we would have seen
a significant decrease in fluorescence since it has been shown that profilin does not bind
univalently. Finally, this would have allowed us to determine the average space between each
PIP2 bound to the glass slide using known equations.16

15

1.3 Results and Discussion
As previously mentioned above, PIPs interact with a vast amount of proteins. Here, we
describe the efficacy of microarray for using PIP probes as lipid mimics to detect certain protein
binding affinities. A previously synthesized PIP2-amine linked probe was printed onto epoxidefunctionalized glass slides purchased from Schott Nexterion®.

Figure 1.7: Immobilization of primary amine to epoxy coated slides.

The amine of the PIP probe cleaves open the epoxide on the slide to form a covalent
bond when immobilized with the print buffer (Arrayit Protein Printing Buffer 2X®). On the glass
slide 16 supergrids are usually printed as described in figure 1.5 with varying concentrations

16

of PIP probe within each supergrid. This is followed by incubation, washing, blocking of
unreacted slide, followed by incubation of protein.

Figure 1.8: Robotic pin printer with 32 pins

Using the SDDC-2 robotic printer from ESI, PIP2 probe was printed onto the epoxidefunctionalized slides. The pin has an uptake volume of 0.25µL/sample, a tip opening of 75 µm,
and delivery volume of 600 pL. Several different buffer types and concentrations were used
when spotting. (TRIS) tris(hydroxymethyl)aminomethane buffer was used first at a
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concentration of 20mM, pH 8.0, and .05% tween additive. One of the first issues of the printing
process was repeatable solid dots as shown in figure 1.3. After experimentation of differing
concentrations up to 200mM TRIS it was determined replicable spots were not achievable with
TRIS. Solvation and replication of dots was achieved with the use of Arrayit Print Buffer. No
further modification was made to print buffer after purchase. After incubation overnight, the
slides were washed with TRIS buffer to remove any unbound probe providing reasonable
results as shown in Figure 1.9-1.10.
To ensure specific interactions between probe and protein the slide needed to be
blocked after ligand immobilization. Blocking conditions were varied with ethanolamine,
diethylamine, and superblock. High fluorescence background was still seen with ethanolamine
concentrations of 20-200 mM, so subsequent assays were used with 200 mM diethylamine and
superblock as both achieved similar results. After one hour of blocking, the slide was washed 3
times with TRIS buffer to remove any traces of block buffer and dried. The supergrids printed
with PIP probe were then incubated in a solution of Profilin protein that ranged from 0 μg to
100 μg in TRIS buffer for one hour. This was followed by washing 3 times with TRIS buffer to
remove unbound protein. Following this, the supergrids were incubated with goat-anti-Profilin
antibody for one hour followed by washing 3 times with TRIS buffer to remove unbound
antibody. Lastly, the supergrids were incubated with rabbit-anti-goat Cy3 tagged antibody for
one hour followed by one wash with TRIS buffer and washed two times with H2O. The slide was
then dried over nitrogen and scanned for fluorescence using slide scanner.
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Figure 1.9: Results of 0-1000 µM PIP2 probe incubated with Superblock, 25 µg
solution of Profilin, 10 µg AP, and 5 µg Cy3 antibody
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Figure 1.10: Results of 0-1000 µM PIP2 probe incubated with Superblock, 20 µg
solution of Profilin, 10 µg AP, and 5 µg Cy3 antibody
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1000

From the previous figures 1.9-1.110 we are able to see that there is binding occurring
between ligand and protein. As the concentration of ligand is increased on the supergrid while
keeping the same amount of profilin on that supergrid we could see that binding was increasing
up to 1000 μM ligand concentration. We were able to successfully use microarray techniques to
show that binding with Profilin and the PIP2 probe can occur on epoxide functionalized glass
slides. The success of printing seemed to be a good portion of the challenging aspect in the
microarray analysis. Ultimately, we printed with the Arrayit Printing Buffer achieving the most
successful results. Blocking conditions of the unreacted slide surface was initially unsuccessful
at lower concentrations of diethylamine below 90 mM. Further optimization of the conditions
employed is necessary to achieve a full slide of supergrids with varying concentrations of
Profilin.
Even though the previously mentioned assays yielded a substantial start to the
studies, further optimization requirements must be employed. A control experiment below was
setup with Atto 550®, a fluorescent molecule attached to biotin. This was printed from
concentrations of 0-500 μM as indicated in figures 1.11-1.12. This showed that using our Arrayit
buffer worked and reestablished proof of concept of the experiment. The one issue with the
control experiment is that the same amount of compound was printed in each row, which
should have led to same amount of mean fluorescence for each row. This inconsistency is one
of the obstacles that we were unable to be overcome in the printing process of our ligand.
Undoubtedly the largest issue with our microarray work is inconsistency. At first the
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printing of the supergrids and amount of solution that repetitively printed was difficult. There
were many variables alone for just this issue, for example, the pin may not have picked up any
solution or not deposited the solution. Secondly the pins need to be cleaned in a specific
manner in between each super grid printing and this could lead to minor changes in the amount
of solution picked up or spotted in the next round of printing. Thirdly the pin opening is quite
small and extensively fragile and proved on more than one occasion to close up and bend
calling for a need to replace pins, which are quite expensive.
Data was analyzed the GenePix® 4000B microarray scanner from Axon instruments, of
which the fluorescence intensities were quantified. The scanner has a 532 nm wavelength laser,
which would scan the slide and show images of the supergrids. The control in the experiments
was the spot of print buffer which contained no PIP2 probe. The spots that had uncharacteristic
results as either lower or higher fluorescence were discarded from the analysis. Ultimately the
main goal was to print a slide such as in figure 1.13 and obtain mean fluorescence of all of the
grids which was never accomplished to date.
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Figure 1.11: Results of 0-500 µM Atto 550 first grid
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Figure 1.12: Results of 0-500 µM Atto 550 second grid
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Figure 1.13: Results of 0-1000 µM PIP2
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Chapter 2:

Design and Synthesis of Inositol
Hexaphosphate probe

2.1 Background and Significance of Inositol Polyphosphates in
Biological Processes
Inositol polyphosphates, or (IPs), are a diverse family of eukaryotic signaling molecules
that control many key cellular processes. Due to the numerous isomers that exist of IPs and
their interconnection, identifying individual pathways with different protein binding partners
have elucidated scientists to present day. In terms of biosynthesis the lipid PIP2 acts as the
precursor to IP3 specifically showing the complex nature of small molecules in the cellular
environment.18

Figure 2.1: Structures of IP5 and IP6. Circled P = phosphate.18
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Strategies have emerged for the synthesis of chemically modified IPs for the
determination of such binding activities. All of the IPs have the myo-inositol core with different
phosphorylation patterns about the cyclohexane ring. The most abundant IPs are myo-inositol
(1,2,3,4,5,6)IP6, “phytate” as commonly referred, IP6 and myo-inositol (1,3,4,5,6)IP5, IP5, both
of which tend to have concentrations generally between 10-100 µM in the cell.6 IP6 and IP5 are
involved in phosphatase and kinase regulation as well as calcium channel aggregations.19

Figure 2.2: Possible roles of IP5 and IP6 in the mechanisms of G-protein coupled
receptor desensitization and down-regulation18
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The negatively charged phosphate groups on IP6 provide aptitude to chelate divalent
and trivalent cations.18 IP6 is a beneficial dietary component found in many plant sources.20
Studies have been suggestive of the importance of various cancers and their associations with
dietary intake. The lack of dietary fiber, certain vegetables, and total dietary fat could lead to a
role in the etiology of the cancer.20 This can be related to the amount of particular small
molecules that play crucial roles in protein pathways.

Figure 2.3: Example of a Calcium channel L- type. Possible roles of IP5 and IP6 in
the mechanisms of G-coupled receptor desensitization and down-regulation. 21

IP5, which lacks a phosphate group at the only axial position on the inositol ring, has a
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variety of roles in cell proliferation,22 as well as being involved with competition of kinases and
phosphatases such as Akt,23 and PDK1,24 and their respective phosphoinositide targets.

Figure 2.4: PDK1 involvement in activation cycle of Akt. PI3K mediates
membrane recruitment of Akt and PDK1, resulting in PDK1-induced Akt
phosphorylation and activation.25

Effectively designing IP probes will enhance the opportunity to successfully study the
protein–IP binding interactions. There are 63 possible variations of IP structure of which only
half or so have been identified to be involved in biological pathways.6 Elucidation of the specific
processes that the IPs are involved in could promote a much better understanding of disease. A
necessity to overcome when associating the synthesis of IPs is awareness of phosphorylation at
specific positions about the inositol ring. There has been a great deal of research into synthetic
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strategies so only a few routes of recent strategy will be covered.6,19,26 Of those cited most
notable are IP3, IP7, IP5, and IP6 have been of interest due to the amount of biological signaling
events they have a role in. Our interest was to make an IP6-biotin molecule to purify protein
targets by affinity chromatography. Previous examples using IP7 showed positive results that
biological activity between target molecule and proteins.26

Scheme 2.1: Synthetic approaches to the desymmetrization of myo-inositol using
resolution steps to produce IPs and PIPs.6
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2.2 Results and Discussion

Scheme 2.2: Synthetic scheme of IP6 analog. P = phosphate

The approach to the biotin linked IP6 analog began with myo-inositol which was first
protected with trimethylorthoformate to produce 25.27 Compound 25 was protected at the 2
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position with a benzoyl group to access 26.28 The orthoformate protecting group was then
removed to provide 27.28 Next, an o-xylene phosphoramidite (PPA) protecting group was
introduced at the five free hydroxyl positions to yield 28.29,26 We next attempted to deprotect
28 selectively at the 2 position with a multitude of different reagents to generate 29. In this
approach it was first attempted to use 1% NaOH and excess NaOMe for which all the xylene
PPA groups were removed. Following further, it was then attempted to try varying amounts of
1%-10% NaOH for deprotection. This resulted in either starting material being recovered or
removal of the xylene PPA groups. Subsequently, it was then attempted to reflux with 5% NaOH
to which removal of the xylene groups happened again. After that, a different approach using
saturated NH3/MeOH and stirring for varying amounts of time from 2 hours to 4 days resulting
in recovery of starting material again. With the aim to remove this protecting benzoyl group it
was then attempted to reflux with saturated NH3/MeOH to which the removal of the xylene
PPA groups happened again.
It has become evident with support from literature that the xylene protecting groups
are not of sufficient stability to withstand the conditions for removal of the benzoyl group as
well as evidence that sterics play a crucial role about the inositol ring.26 One approach would be
to protect at the 4 and 6 positions on the inositol ring after introduction of the benzoyl
protecting group. Silyl groups could be advantageous in this effort as they are known to resist
being removed by acid. The next step would be to deprotect the orthoformate group and yield
a full silyl protected moiety which would be much less bulky. Additionally it could be conceived
that protection of compound 27 with five silyl protecting groups directly to achieve a less
hindered molecule.
30

Experimental
1D-4,5-O-(tert-Butyldiphenylsilyl)-2,3-O-(D-1’,7’,7’-trimethyl[2.2.1]bicyclohept-2’ylidene)-myoinositol (11)

To the stirred solution of triol (10) (1.345g, 2.43 mmol) in pyridine (15 mL) and methylene
chloride (2.5 mL) at -40 oC was added slowly benzoyl chloride (535µL, 5.10 mmol). The mixture
was slowly warmed-up to room temperature and solvent removed by evaporation. The crude
product was dissolved in ethyl acetate, washed with water and chromatographed on silica gel
(hexane/acetone gradient) to afford pure (11) (1.33 g, 72%) as a colorless solid.
Characterization matched prior literature.14
1

H NMR (CDCl3) δ 0.90 (s, 3H), 1.11 (s, 9H), 1.13 (m,7H), 1.31 (d, J = 12.9 Hz, 1H), 1.43 (d tr, J =

7.8, 3.9 Hz, 1H), 1.69 (m, 1H), 1.72 (m, 1H), 1.80 (m, 1H), 1.90 (m, 1H), 4.02 (tr, J = 6.7 Hz, 1H),
4.09 (m, 2H), 5.13 (tr, J = 8.5 Hz, 1H), 5.63 (m, 1H), 7.25-7.50 (m, 12H), 7.70-7.96 (m, 8H).
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1D-4,5-O-(tert-Butyldiphenylsilyl)-myo-inositol (12)

The solution of the alcohol (11) (830 mg, 1.1 mmol) in chloroform (15 mL) was treated with
trifluoroacetic acid (3.15 mL) containing 5% v/v water. After 18 h at room temperature, the
solvent was removed and the remaining trifluoroacetic acid was neutralized with triethylamine
(0.7 mL). Chromatography on silica gel (hexane/acetone gradient) afforded pure (12) (479 mg,
73%) as a white foam. Characterization matched prior literature.14
1

H NMR (CD3OD) δ 1.13 (s, 9H), 3.51 (dd, J = 10.0, 2.4 Hz, 1H), 3.81 (tr, J = 2.64 Hz, 1H), 4.30 (tr,

J = 9.6 Hz, 1H), 5.20 (tr, J = 9.8 Hz, 1H), 5.71 (tr, J = 10.0 Hz, 1H), 7.29-7.51 (m, 12H), 7.82-7.91
(m, 8H).
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1D-1-O-(tert-Butyldiphenylsilyl)-3,4,5-O-trisbenzoyl-myo-inositol (13)

The solution of triol (12) (277 mg, 0.45 mmol) in dichloromethane (5 mL) was added
triethylamine (190 µL, 1.36 mmol) and 4-dimethylaminopyridine (55 mg, 0.45 mmol) at -40 oC.
Benzoyl chloride (72 µL, 0.68 mmol) was added drop wise and stirred overnight at room
temperature. After aqueous workup the mixture was chromatographed on silica gel
(hexane/acetone gradient) giving (13) (292 mg, 88%) as a white solid. Characterization matched
prior literature.30
1

H NMR (CDCl3) δ 8.0-7.25 (m, Ph, 25 H), 6.20 (tr, H-4, J = 10.3 Hz, 1H), 5.38 (tr, H-5, J = 9.9 Hz,

1H), 5.16 (dd, H-3, J = 2.7, 10.4 Hz, 1H), 4.41 (d tr, H-6, J = 9.5, 4.0 Hz, 1H), 4.23 (tr, H-2, J = 2.7
Hz, 1H), 3.90 (dd, H-1, J = 2.7, 9.2 Hz, 1H), 1.13 (9 H, Me).
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3,4,5-O-Tribenzyl-2,6-O-bis(benzyloxymethyl)-1-O-(tert-butyldiphenylsilyl)-D-myo-inositol (14)

Diisopropylethylamine (1 mL, 6.13 mmol) and dichloroethane (8mL) were added to diol (13)
(560 mg, 0.766 mmol). Benzyl chloromethyl ether (849 µL, 6.13 mmol) was added and reaction
mixture was stirred at reflux for 24 h. After reaction finished, water was added and extraction
with dichloromethane. The mixture was chromatographed on silica gel (hexane/acetone
gradient) to yield (14) (573 mg, 77%) as a clear solid. Characterizations matched previous
reports.4
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2,6-O-Bis(benzyloxymethyl)-1-O-(tert-butyldiphenylsilyl)-D-myoinositol (15)

A 1% sodium hydroxide solution (4 mL) and dichloromethane (4 mL) were added to a solution
of (14) (240 mg, 0.25 mmol) in methanol (8 mL). The mixture was stirred for 18 hours at room
temperature. The solvent was removed and the residue purified by chromatography on silica
gel (hexane/acetone gradient) to yield (15) (99 mg, 72%) as a clear solid. Characterizations
matched previous reports.4
1

H NMR (CDCl3) δ 7.68 (t, J = 7.2 Hz, 4H), 7.45–7.25 (m, 16 H), 4.94 (d, J = 6.8 Hz, 1 H), 4.75–

4.65 (m,3 H), 4.54–4.51 (m, 3 H), 4.42 (d, J = 11.6 Hz, 1 H), 4.30 (br. s, 1H), 3.81–3.72 (m, 2 H),
3.66–3.54 (m, 3 H), 3.20–3.13 (m, 2 H), 2.75 (br. s, 1 H), 1.04 (s, 9 H) ppm.
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2,6-O-Bis(benzyloxymethyl)-1-O-(tert-butyldiphenylsilyl)-D-myo-inositol 3,4,5-Tris(dibenzyl
phosphate) (16)

Dibenzyl N,N-diisopropylphosphoramidite (294 µL, 1.22 mmol) was added to a solution
of alcohol (15) (103 mg, 0.15 mmol) and 1H-tetrazole (3.1 mL, 1.4 mmol, 0.45 M in acetonitrile)
in dichloromethane (4 mL) under nitrogen, and the mixture was stirred at room temperature
for 18 h. The reaction solution was cooled to –20 °C, and meta-chloroperoxybenzoic acid (220
mg, 1.27 mmol) was added. The mixture was warmed to room temperature and stirred for 3 h.
The solvent was removed and the residue purified by flash chromatography on silica gel
(hexane/acetone gradient) to access (16) (210 mg, 98%) as a clear solid. Characterizations
matched previous reports.4
1

H NMR (CDCl3): δ 7.76–7.67 (m, 4 H), 7.38–7.05 (m, 46 H), 5.15–4.88 (m, 12 H), 4.83–4.64 (m,

7 H), 4.54–4.48 (m, 2 H), 4.37–4.26 (m, 2 H), 4.08 (t, J = 12 Hz, 1 H), 3.98–3.91 (m, 2H), 1.07 (s,
9H) ppm.
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Dibenzyl N,N-diisopropylphosphoramidite (88)

Diisopropylamine (7.8 mL, 55.8 mmol) was added drop-wise to a solution of phosphorus
trichloride (2.6 mL, 26.1 mmol) in (70 mL) hexane at -20o C. After addition the sludge was
stirred for 1.5h at room temp. The crude was filtered and washed with hexane and dried. Ether
(60 mL) was added to the dried crude at -20 oC from which a mixture of benzyl alcohol (5.0 mL,
48.3 mmol), triethylamine (6.7 mL, 48.3 mmol), and ether (60 mL) were added drop wise. After
addition the mixture was stirred for 6h and was filtered over ethyl acetate and dried while
chilled. The residue was purified by flash chromatography on silica gel over (hexane/ethyl
acetate/ triethylamine) to yield pure (88) (4.80 g) as a clear liquid. Characterizations matched
previous reports.4
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2,6-O-Bis(benzyloxymethyl)-D-myo-inositol 3,4,5-Tris(dibenzylphosphate) (17)

A solution of fully protected inositol (16) (225 mg, 0.15 mmol) in tetrahydrofuran (8 mL) was
treated with tetrabutylammonium fluoride trihydrate (147 mg, 0.47 mmol) and stirred at room
temperature for 18 h. Following concentration, the residue was purified by chromatography on
silica gel (hexane/acetone gradient) to give alcohol (17) (74 mg, 50%) as a syrup.
Characterizations matched previous reports.4
1

H NMR (CDCl3) δ 7.32–7.15 (m, 40 H), 5.14–4.84 (m, 16 H), 4.70–4.60 (m, 5 H), 4.48–4.40 (m, 3

H), 4.28–4.19 (m, 2 H), 3.85 (t, J = 9.4 Hz, 1 H), 3.48–3.44 (m, 1 H) ppm.
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Benzyl (6-Benzyloxycarbonylaminohexyl) 2,6-O-Bis(benzyloxymethyl)-D-myo-inosit-1-yl
Phosphate 3,4,5-Tris(dibenzyl phosphate) (18)

To alcohol (17) (74 mg, 0.062 mmol), 1H-tetrazole (1.0 mL, 0.45 mmol, 0.45 M in acetonitrile),
dichloromethane (15 mL), and the cbz-aminohexanol phosphoramidite (700 mg, 1.54 mmol),
were added and the mixture was stirred at room temperature for 18 h. The reaction solution
was cooled to –60 °C, and meta-chloroperoxybenzoic acid (750 mg, 57–86%) was added. The
mixture was stirred at this temperature for 60 min and slowly warmed to room temp. The
solution was diluted to 60 mL with dichloromethane, washed with saturated aqueous sodium
hydrogen carbonate (30 mL), and the aqueous phase was extracted with dichloromethane (60
mL). The organic phase were dried with magnesium sulfate, filtered, and concentrated.
Purification by chromatography on silica gel (hexane/acetone gradient) was used to afford
product (18) (70 mg, 71%) as clear syrup. Characterizations matched previous reports.4
1

H NMR (CDCl3) δ 7.32–7.17 (m, 50 H), 5.13–4.81 (m, 21 H), 4.76–4.52 (m, 5 H), 4.45–4.17 (m, 4

H), 3.94–3.82 (m, 2 H), 3.09–3.03 (m, 2 H), 1.46–1.18 (m, 8H) ppm.
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Cbz-Aminohexanol (91)

To a mixture of 6 amino-1 hexanol (2.0 g, 1.7 mmol), methanol (10 mL), and triethylamine (5.45
mL, 2.0 mmol) was added drop wise benzyl chloroformate and stirred overnight. The mixture
was dried and extracted with dichloromethane (150 mL) and potassium hydrogen sulfate (50
mL). The brown (91) (1.5 g, 35%) was carried on without further purification. Characterizations
matched previous reports.4
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Benzyloxybis(diisopropylamino) phosphane (92)

Ether (40 mL) and benzyloxybis(diisopropylamino) phosphane (1.52 g, 8.27 mmol) were mixed
at 0 oC. Separately benzyl alcohol (850 µL, 8.27 mol), triethylamine (1.15 mL, 8.27 mmol), and
ether (10 mL) were mixed and added drop wise to phosphine mixture. After stirring for two
hours at 0 oC the salt was filtered and purified by column chromatography on silica gel
(hexane/triethylamine) to yield (92) (1.47 g, 58%) as a clear liquid. Characterizations matched
previous reports.4
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Cbz-Aminohexanol Phosphoramidite (93)

1H-tetrazole (4.6 mL of a 0.45 M solution in acetonitrile, 2.07 mmol) and
benzyloxybis(diisopropylamino) phosphane (92) (1.0 g, 2.96 mmol) were added to a
solution of cbz-aminohexanol (91) (500 mg, 1.9 mmol) in dichloromethane (30 mL) under
nitrogen. This mixture was stirred at room temperature for 2 h, at which point the solution was
extracted with dichloromethane (3X80 mL) from saturated sodium hydrogen carbonate (80
mL). The combined organic phases were dried with magnesium sulfate, filtered, and
concentrated, and the residue was purified by chromatography on silica gel (hexane/ethyl
acetate/triethylamine, 100:10:1). The colorless liquid (93) (800 g, 1.7 mmol) was
passed on to the next step without further purification.
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1-(6-Aminohexyl sodium phosphate)-D-myo-inositol 3,4,5-Tris(disodium phosphate) (19)

Palladium hydroxide (20%) (14 mg) on charcoal was added to a solution of (18) (70mg, 0.044
mmol) in methanol (10 mL). The mixture was then stirred at room temperature with 1 atm of
hydrogen (balloon) for 4 d. The catalyst was removed by filtration and the residue washed with
methanol. The solvent was removed, and the crude product was dissolved in water and stirred
with Chelex 100 resin (Sigma, Na+ form) for 3 h. The resin was removed by filtration and the
filtrate lyophilized to give the corresponding amino conjugate (19) (13mg, 18%).
Characterizations matched previous reports.4
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myo-inositol Monoorthoformate (25)

To the commercially available (24) (10.8 g, 0.06 mmol) was added dimethylformamide (160
mL), para-toluenesulfonic acid (3.0 g, 0.016 mmol), and trimethyl-ortho formate (12.5 mL, 0.12
mmol). The solution was reflux at 110 oC for 18 hours. After cooling to room temperature
sodium hydrogen carbonate (10 mL) was added and stirred for 30 minutes. The crude
concentrated, and the residue was purified by chromatography on silica gel
(dichloromethane/methanol gradient) to afford the pure (25) (9.75 g, 84%) as a white solid.
Characterizations matched previous reports.27
'H NMR (D20) δ 4.23 (2 H, m), 4.26 (1 H, m), 4.33 (1 H, m), 4.57 (2 H, t, J = 3.8 Hz), 5.59 (1 H, d, J
= 0.8 Hz)
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2-O-Benzoyl-myo-inositol 1,3,5-Orthoformate (26)

To a solution of (25) (1.03 g, 5.4 mmol) in anhydrous pyridine (30 mL) were added benzoyl
chloride (0.7 mL, 5.95 mmol) and a catalytic amount of 4-dimethylaminopyridine at 0 oC. The
mixture was stirred at room temperature overnight. Ethyl acetate was added to the reaction
system and washed with potassium hydrogen sulfate, sodium hydrogen carbonate, and brine.
After the solvent was removed, the residue was purified by chromatography on silica gel (ethyl
acetate/ hexane gradient) to afford the pure (26) (1.16 g, 72%) as a white solid.
Characterizations matched previous reports.28
'H NMR (CD3OD/CDCl3 = 1/9, v,v) δ 4.21 (3 H, m), 4.30 (2 H, m), 5.30 (2 H, m), 7.21 (3 H, m,
aromatic), 7.58 (2 H, m, aromatic)
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2-O-Benzoyl-myo-inositol (27)

To a solution of (26) (250 mg, 0.85 mmol) in methanol (12 mL) was added concentrated
hydrochloric acid (6 mL). The mixture was stirred at room temperature for 60 minutes. The
solvent was evaporated to dryness. The residue was dried under vacuum to give (27)
quantitatively. Characterizations matched previous reports.28
1

H NMR (D2O) δ = 3.26 (1H, t, J = 7.3 Hz), 3.66 (4H, m), 5.55 (1H, s, H-2), 7.41 (2H, t, J = 7.6 Hz,

aromatic), 7.56 (1H, t, J = 7.6 Hz, aromatic), 7.91 (2H, d, J = 7.6 Hz, aromatic).
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2-O-Benzoyl-(1,3,4,5,6)-pentakis(o-xylene phosphate)-myo-inositol (28)

To a solution of (27) (10 mg, 0.32 mmol) in dichloromethane (15 mL) at 0 oC were added 1Htetrazole (12.5 mL of a 0.45 M solution in acetonitrile, 5.71 mmol) and phosphine (1.0 mL, 12
eq) and stirred for one hour, then room temp for four hours. The mixture was cooled to -78 oC
and oxidized with meta-chloroperoxybenzoic acid (1.7 g) for 30 minutes, then room
temperature for 45 minutes. Addition of dichloromethane (20 mL) and sodium bisulfate (50 mL)
to the reaction mixture and collection of the organic layer with drying over magnesium sulfate.
After the solvent was removed, the residue was purified by chromatography on silica gel (ethyl
acetate/ hexane gradient) to afford the pure (28) (370 mg, 88%) as a white solid. Compounds of
similar structure and symmetry were reported in the literature and compared to for
analysis.29,26
1

H NMR (CDCl3) δ = 4.90-5.30 (14H, m), 5.39-5.45 (4H, m), 5.55 (2H), 5.64 (4H, m), 6.4 (1H, s),

7.20-7.50 (21H, m, aromatic), 7.59 (1H, t, aromatic), 8.08 (2H, d).
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N, N-Diethylamino-5, 6-benzo-1, 3, 2-dioxaphosphane (50)

To the solid 1, 2-benzenedimethanol (4.85 g, 35.0 mmol) was added hexaethyl phosphorus
triamide (9.2 mL, 35.0 mmol) and the mixture was condensed at 100 oC without lid until the
evolution of diethylamine had ended. The pure (50) (5.10 g, 65%) was recovered by vacuum
distillation. Characterizations matched previous reports.31
1

H NMR (CDCl3) δ = 1.20 (6H, t), 3.18 (4H, m), 4.90 (2H, q), 5.20 (2H, m), 7.15-7.30 (4H, m,

aromatic).
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